Luitpold Pharmaceuticals Chooses BioClinica Express EDC

Vendor Flexibility and Technology Suite Cited as Key to Selection

Luitpold Pharmaceuticals Chooses BioClinica Express EDC

Jim Dorsey, 267-757-3040orTrade Media:Rachel Summers, 484-342-3600orInvestor:Michael Porter, 212-564-4700orFinancial Media:Bill Gordon, 212-564-4700

BioClinica, Inc. (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced that Luitpold Pharmaceuticals, a pioneer in the development and marketing of a wide variety of drugs and medical devices, will use BioClinica’s Express Electronic Data Capture ("EDC") system for multiple upcoming clinical trials.

Luitpold selected BioClinica’s Express EDC after a comprehensive search and vendor evaluation process, citing the company’s flexibility during the bidding process and advanced technology as important factors in the decision.

“The transparency of BioClinica’s solutions and accessibility of the project management team will make BioClinica a true partner in the clinical trial process,” said Marc L. Tokars, Vice President of Clinical Operations for Luitpold. “We’re excited by the possibilities that BioClinica’s advanced technology will bring to Luitpold’s future clinical trials.”

BioClinica’s Express EDC makes every part of the clinical trial process more efficient and easier to manage. Express is a comprehensive EDC solution that uses time-tested, stable technology to provide a central hub to coordinate and organize the collection and dissemination of clean data, adding speed and quality to every part of the clinical trial process.

“We are pleased Luitpold has selected BioClinica’s Express EDC for their upcoming trials,” said Peter Benton, President of BioClinica’s eClinical division. “Luitpold has a proud tradition of pharmaceutical innovation, and we are extremely pleased that BioClinica’s comprehensive suite of eClinical solutions will help them continue to bring new drugs to market.”

Luitpold Pharmaceuticals, Inc., a Daiichi Sankyo Group Company, headquartered in Shirley, NY, manufactures over 80 pharmaceutical products including Venofer® (iron sucrose injection, USP), the # 1 selling IV iron therapy in the U.S., which are distributed through its human health subsidiary, American Regent, Inc. Luitpold Pharmaceuticals, also markets dental bone regeneration products and veterinary pharmaceuticals through its Osteohealth and Animal Health divisions respectively. Sprix® (ketorolac tromethamine) Nasal Spray is marketed through its Regency Therapeutics Division. For more information on Luitpold or any of its divisions and products, please visit:

BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit

Suggested Articles

Loretta Itri, M.D. has been helping Immunomedics out with its troubled antibody-drug conjugate. Now, she’s signing on as its chief medical officer.

Light Chain Bioscience, a unit of Swiss biotech Novimmune, has been handed a nice royalty milestone check from partner Takeda.

The fund received money from Chinese organizations inside and outside the biopharma industry, enabling CICC Capital to ease past its financing goal.